MEMORANDUM & ORDER
Defendants and Counter-Plaintiffs Houbigant, Inc. and Etablissement Houbigant bring various counterclaims arising out of alleged breaches of a trademark licensing agreement and other collateral agreements. Plaintiffs and Counter-Defendants move to dismiss Counterclaims II-IX pursuant to Fed.R.Civ.P. 12(b)(6). For the reasons set forth below, Counter-Defendants’ motion is GRANTED in part and DENIED in part.
I. BACKGROUND 1
A. The Parties
Counter-Plaintiffs Houbigant, Inc. and Etablissement Houbigant (collectively, “Houbigant” or “Plaintiffs”) are engaged in the business of licensing fragrance product trademarks. (Countercl. ¶ 63.) Counter-Defendant IMG Fragrance Brands, LLC (“IMG Brands”), a wholly-owned subsidiary of Counter-Defendant IMG Holdings, Inc. (“IMG Holdings”), licenses eer
B. The License Agreement
On December 19, 2003, Houbigant entered into a License Agreement with IMG Brands whereby IMG Brands, as Licensee, was given the exclusive right to use various trademarks including Chantilly®, White Chantilly®, and Demi-Jour among others (the “Products”). (Id. ¶ 80-81.) Although the License Agreement was scheduled to expire on December 31, 2008, Houbigant maintains that it terminated the agreement by notifying IMG Brands on December 28, 2008. (Id. ¶ 82.)
The License Agreement set forth several conditions with which IMG Brands had to comply in order to receive Houbigant’s continuing consent to use the trademarks. Some of these conditions included:
(a)IMG Brands had the ability to manufacture and promote the sales of the Products (Countercl., Ex. A § 3);
(b) Any sub-licensee would need to be preapproved by Houbigant and would have to abide by the terms of the License Agreement (id.);
(c) Facilities used to manufacture the Products must be disclosed to Houbigant, and Houbigant reserved the right to inspect those facilities (id. § 7(b), (e));
(d) IMG Brands would pay periodic royalties to Houbigant on the first day of each month throughout the duration of the License Agreement (id. § 9);
(e) Upon termination of the agreement, IMG Brands would be permitted to sell Products for an additional 135 days, known as the “Relevant Period” (id. § 18);
(f) Either party could enforce an amendment to the License Agreement so long as the amendment was in writing and signed by both parties (id. § 28); and
(g) On the thirtieth day after termination of the License Agreement, IMG Brands had the option to purchase the trademarks for $1,000, so long as IMG Brands made payment for any outstanding Royalty Payments on or before the twenty-ninth day following termination. (Id. § 9)
In January 2004, IMG Brands appointed DCF as a sublicensee. (Comply 88.) In October 2008, Houbigant alleges that IMG Brands and DCF engaged several subcontractors to manufacture the Products and that the manufacturing facilities the subcontractors used were not specified in the License Agreement. (Id. ¶ 90; Ex. A § 7(e).)
C. The Supplemental Royalty Agreement
The Supplemental Royalty Agreement (“SRA”) was executed on December 19,
D. Subsequent Agreements
i. The Fifth Deferral Agreement
On August 27, 2008, Houbigant and IMG Brands entered into a Fifth Deferral Agreement (“FDA”) which set forth a payment schedule for IMG Brands to pay the past due royalty payments owed pursuant to the License Agreement. (Id. ¶¶ 154-55.) The FDA contained several other conditions and also incorporated the previous four deferral agreements. (Id. ¶¶ 158-164.) Some of the amendments made by the prior deferral agreements included: (1) reducing the cure period from thirty days to five days (id. ¶ 164); (2) requiring IMG Brands to pay a Deferral Fee of $350,000 no later than the date of expiration of the License Agreement (id. ¶ 165); and (3) requiring yet another deferral fee of $175, 000 (id. ¶ 166.).
Houbigant alleges that IMG Brands represented that it had obtained all of the necessary approvals from its lenders to enter into the FDA. (Id. ¶ 171.) Houbigant further claims that IMG Brands, the Zohar Funds, and Tilton knew of the FDA and performed pursuant to its terms until December 31, 2008. In fact, Houbigant received at least one scheduled payment from Wells Fargo, one of IMG Brands lenders. (Id. ¶ 177.) It was not until December 31, 2008 that IMG Brands, through Patriarch, informed Houbigant that the FDA was unenforceable because it modified the terms of the License Agreement without the consent of Wells Fargo. (Id. ¶ 190.) Therefore, IMG Brands did not make the remaining payments. (Id. ¶ 188.)
ii. The Consulting and Product Development Agreement
In order to assist DCF’s sale of Houbigant products, the parties entered into a Consulting and Product Development Agreement (“CPDA”). (Id. ¶ 192.) Under the terms of the agreement, Houbigant was to provide consulting services in exchange for a fee that equaled the outstanding royalty payments. (Id.) Houbigant alleges that, although its services were never requested, DCF confirmed that its obligation to Houbigant under the CPDA was $1,139,736. (Id. ¶ 195.)
E. The Alleged Breaches
Houbigant alleges that IMG Brands and DCF caused Products to be manufactured at unauthorized locations
(Id.
¶¶ 92, 196.) Houbigant further alleges that IMG Brands and DCF, both under the direction of Patriarch and Tilton, breached the License Agreement in myriad ways, including: selling Products after December 31,
II. ANALYSIS
A. Motion to Dismiss Standard
To survive a motion to dismiss under Rule 12(b)(6), “a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’ ”
Ashcroft v. Iqbal,
— U.S. -,
In
Iqbal,
the Supreme Court set forth a “two-pronged” approach for analyzing a motion to dismiss.
Iqbal,
B. Counts II and IV-Breach of the License Agreement and the SRA
In its second claim for relief, Houbigant alleges that Defendants IMG Brands, DCF, Patriarch, and Zohar II breached the License Agreement and, in its fourth claim for relief, Houbigant alleges that IMG Holdings breached the SRA. The Counterclaims adequately state a claim for breach of the License Agreement as against IMG Brands and DCF and a claim for breach of the SRA as against IMG Holdings. Because neither Patriarch nor Zohar II was a signatory to the License Agreement, neither can be held liable for breach of contract. Accordingly, Defendants’ motion to dismiss Count II is granted in part and denied in part, and their motion to dismiss Count IV is denied.
In order to plead a breach of contract claim, a plaintiff must allege: “(1) the existence of a contract; (2) performance by the party seeking recovery; (3) nonperformance by the other party; and (4) damages attributable to the breach.”
Ixe Banco, S.A. v. MBNA America Bank, N.A.,
No. 07 Civ. 0432,
Houbigant’s allegations that Patriarch and Zohar II are also liable for breach of the License Agreement are insufficient to state a cause of action. IMG Brands is a wholly-owned subsidiary of IMG Holdings. (Countercl. ¶ 66.) As alleged in the Counterclaims, Zohar II acquired 51% of the stock of IMG Holdings on or about October 17, 2008.
(Id.
¶ 69.) Patriarch is the collateral manager of the Zohar Funds.
(Id.
¶ 71.) Under New York law, a corporate parent is not automatically liable for the acts of its wholly owned subsidiary, even where the parent and subsidiary corporations have interlocking directorates.
See Beck v. CONRAIL,
Here, the Counterclaims do not adequately allege Patriarch’s or Zohar II’s domination and control of IMG Brands. In considering whether a parent corporation exercised “complete domination” over its subsidiary, courts consider such factors as:
(1) disregard of corporate formalities; (2) inadequate capitalization; (3) intermingling of funds; (4) overlap in ownership, officers, directors, and personnel; (5) common office space, address and telephone numbers of corporate entities; (6) the degree of discretion shown by the allegedly dominated corporation; (7) whether the dealings between the entities are at arms length; (8) whether the corporations are treated as independent profit centers; (9) payment or guarantee of the corporation’s debts by the dominating entity, and (10) intermingling of property between the entities.
Freeman v. Complex Computing Co.,
Furthermore, Houbigant’s argument that Patriarch and Zohar II succeeded to IMG Brands’ liabilities pursuant to the successor clause in the License Agreement is unavailing. The License Agreement provides that the “Agreement shall be binding on and enure to the benefit of the successors and assigns of both parties hereto and all persons or entities succeeding to or acquiring the business now carried on by [Houbigant] or [IMG Brands].” (Countercl., Ex. A § 31.) As discussed above, Zohar II acquired an interest in IMG Brands’ parent, IMG Holdings, and Patriarch is the collateral manager for Zohar II. Therefore, neither Zohar II nor Patriarch can be deemed a successor to IMG Brands, as neither entity acquired an interest in IMG Brands. Moreover, the Counterclaims lack any allegation that either Zohar II or Patriarch expressly assumed the obligations of the License Agreement.
See Sillman v. Twentieth Century-Fox Film Corp.,
Finally, the Counterclaims adequately allege a breach of the SRA by IMG Holdings. Houbigant alleges that, pursuant to the SRA, it was entitled to (1) notice of a potential change in control transaction whereby an entity would acquire 50% or more of the equity of IMG Holdings, and (2) a supplemental royalty payment equaling a percentage of the consideration received by IMG Holdings for the acquisition. (Countercl. ¶¶ 139, 143; Ex. B §§ 1, 2.) Houbigant alleges that it never received notice that the Zohar Funds sought to acquire a 75% stake in IMG Holdings and that it never received a percentage of the consideration IMG Holdings received for the acquisition. (Countercl. ¶¶ 144, 146.) The alleged consideration received by IMG Holdings consisted of the Zohar Funds’ release of over $20 million in personal guarantees by its then-CEO, Isaac Cohen. (Id. ¶ 146.)
Although IMG Holdings contends that the release of Cohen’s guarantee did not constitute a transfer of “economic value” to IMG Holdings, thereby negating its duty to make a supplemental royalty payment to Houbigant (see Def. Mem. at 18), this argument is inappropriate on a motion to dismiss. This Court must accept Houbigant’s allegations as true, and here, Houbigant adequately alleges that IMG Holdings received valuable consideration in exchange for Zohar IPs acquisition. (Countercl. ¶ 146.) Regardless, Houbigant adequately alleges that it was entitled to notice if IMG Holdings received inquiries from potential purchasers and that it never received such notice. (Id. ¶¶ 138-40, 144.) Accordingly, IMG Holdings’ motion to dismiss Count IV is denied.
C. Counts III and V — Tortious Interference
i. Zohar Funds and Patriarch
In its third claim of relief, Houbigant alleges that Zohar I and Zohar III induced IMG Brands to breach the License Agreement. 3 In its fifth claim of relief, Houbigant alleges that Patriarch, Tilton, and the Zohar Funds induced IMG Holdings to breach the SRA. Because the Zohar Funds and Patriarch have an economic interest in IMG Holdings and IMG Brands, the parties cannot be liable for tortious interference absent sufficient allegations of malice, fraud or illegality. Houbigant’s conclusory allegations do not meet the pleading standard set forth in Iqbal, nor do they plead fraud with the necessary particularity; as such, the claim must be dismissed. Moreover, the Counterclaims do not adequately allege that Tilton acted so far outside her scope as Chief Executive Officer of Patriarch as to make her liable for tortious interference. Therefore, Defendants’ motion to dismiss Counts III and V are granted.
Under New York law, a claim for tortious interference requires “the existence of a valid contract between plaintiff and a third party, defendant’s knowledge of the contract, defendant’s intentional procurement of the third-party’s breach of the contract without justification, actual breach of the contract, and damages resulting therefrom.”
Lama Holding Co. v. Smith Barney Inc. et. al.,
Here, Houbigant acknowledges that the Zohar Funds and Patriarch have an economic interest in IMG Holdings-the parent of IMG Brands. (Countercl. ¶¶ 68-71 (alleging that Zohar Funds had a 75% interest in IMG Holdings and that Patriarch was the collateral manager of the Zohar Funds).);
see Hirsch,
In characterizing Defendants’ conduct as “malicious,” Houbigant alleges that the Zohar Funds and Patriarch acted “without justification.” (Countercl. ¶¶ 201, 227, 236.) Such allegations, without more, are inadequate.
See Rather v. CBS Corp.,
Additionally, Houbigant’s claims that “IMG Brands (and the other Counter-Defendants)” committed fraud by withholding from Houbigant that IMG Brands had obtained the consent of all the lenders “relative to each deferral agreement” are wholly insufficient under Iqbal, let alone under the heightened pleading standard required under Rule 9(b). Moreover, as will be discussed in Section II.C, infra, because Houbigant’s and IMG Brands’ relationship was a contractual one as opposed to a fiduciary one, IMG Brands did not have a duty to disclose to Houbigant, and therefore, its alleged omissions were not fraudulent.
Finally, Houbigant’s allegations that Defendants induced IMG Brands’ and
As for the License Agreement, any alleged inducements by the Zohar Funds or Patriarch are also only breach of contract claims, not illegal activity.
Affiliated Hospital Prods., Inc. v. Merdel Game Mfg. Co.,
ii. Tilton
Houbigant’s tortious interference claim against Tilton, in her individual capacity, also fails. As discussed above, the general rule is that a claim for tortious interference will lie only against a stranger who improperly interferes with a contract between two contracting parties.
See, e.g., Finley v. Giacobbe,
Here, aside from general allegations that Defendants operated under the direction of Tilton, Houbigant makes no claim that Tilton acted to interfere with the License Agreement or the SRA for her own personal gain. Merely asserting that Tilton caused IMG Brands, DCF, Patriarch, and IMG Holdings to breach their respective agreements fails to meet the enhanced pleading requirement under New York law to hold corporate officers personally liable. Accordingly, Tilton’s motion to dismiss Counts III and V is granted.
D. Count VI — Fraud
Houbigant’s sixth cause of action for fraud alleges two different types of fraudulent behavior. First, Houbigant alleges that IMG Brands and DCF failed to disclose to Houbigant multiple events of default, which Houbigant claims, if it had been aware of such breaches, it would have terminated the License Agreement. (Countercl. § 242.) Houbigant further alleges that IMG Brands misrepresented to Houbigant that it had obtained all of the necessary lender consents it needed to enter into the deferral agreements. (Id. § 245.) For the reasons set forth below, the claim is dismissed.
To state a cause of action for fraud in New York, a plaintiff must allege: (1) a material false representation; (2) intent to defraud; (3) reasonable reliance upon the misrepresentation; and (4) resulting damages.
See Lama Holding Co. v. Smith Barney, Inc.,
First, Houbigant’s argument that the parties’ relationship was not merely contractual in nature but in fact rose to the level of a fiduciary relationship is not supported either by the allegations in the Counterclaims or by controlling law. Houbigant contends that the terms of the License Agreement and the FDA establish a fiduciary relationship. (Opp. at 14.) However, nothing in the FDA implies that IMG Brands owes fiduciary duties to Houbigant
(see
Countercl., Ex. C), and the License Agreement, other than setting forth the parties’ rights and obligations to each other, does not state that IMG Brands (or its sublicensee, DCF) owes Houbigant any heightened duty of trust or confidence
(see id.,
Ex. A). In New York, “parties to a commercial contract do not ordinarily bear a fiduciary relationship to one another unless they specifically so agree.”
Calvin Klein Trademark Trust v. Wachner,
Second, although Houbigant’s claim that IMG Brands misrepresented to Houbigant that it had obtained the consent of the lenders to enter into the FDA would satisfy the second Bridgestone/Firestone exception, Houbigant did not plead the fraud with particularity. Therefore, Houbigant is granted leave to replead the alleged fraudulent misrepresentations made by Mr. Cohen in accordance with Fed. R.CivJP. 9(b).
To satisfy the second
Bridgestone/Firestone
factor, the plaintiff must allege that
In order to plead fraud, Houbigant must comply with the Federal Rules, in particular Rule 9(b), which states: “In alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake. Malice, intent, knowledge, and other conditions of a person’s mind may be averred generally.” Fed.R.Civ.P. 9(b). The Court of Appeals “has read Rule 9(b) to require that a complaint [alleging fraud] ‘(1) specify the statements that the plaintiff contends were fraudulent, (2) identify the speaker, (3) state where and when the statements were made, and (4) explain why the statements were fraudulent.’ ”
Rombach v. Chang,
Before Houbigant executed the Fifth Deferral Agreement, IMG Brands, then-CEO, Isaac Cohen, represented to Houbigant that IMG Brands had obtained Wells’ consent to the terms of the Fifth Deferral Agreement as they had been negotiated by the parties through the conclusion of such negotiations.
(Countercl. ¶ 169.) This sole allegation falls woefully short of the particularity required by the Federal Rules. Houbigant has identified both the content of the misrepresentation and who made the misrepresentation but has failed to identify when the misrepresentation was made, where it was made, and how it was made. Consequently, because this allegation may allow Houbigant to survive a Bridgestone/Firestone challenge, Houbigant is granted leave to replead this allegation with the particularity required by Rule 9(b).
As to the third and final exception of
Bridgestone/Firestone,
Houbigant has not pleaded “special damages [ ] caused by the misrepresentation and unrecoverable as contract damages.”
Bridgestone/Firestone,
Accordingly, because neither IMG Brands nor DCF owed Houbigant any special or fiduciary duty, the fraudulent concealment claim is dismissed. Moreover,
E. Count VII — Accounting
Under New York law, to state a claim for accounting, a plaintiff must establish four conditions: “(1) relations of a mutual and confidential nature; (2) money or property entrusted to the defendant imposing upon him a burden of accounting; (3) that there is no adequate legal remedy; and (4) in some cases, a demand for an accounting and a refusal.”
Pressman v. Estate of Steinvorth,
F. Count VIII-Account Stated
The Counterclaims adequately plead a claim for an account stated. To state a claim for an account stated, the plaintiff must plead that: “(1) an account was presented; (2) it was accepted as correct; and (3) debtor promised to pay the amount stated.”
The Haskell Co. v. Radiant Energy Corp.,
No. 05-CV-4403,
Here, Houbigant’s Counterclaims contain allegations that Houbigant and DCF entered into a series of agreements that, together, constituted the CPDA. (Countercl. ¶ 192.) Moreover, in December 2008, Houbigant alleges it received correspondence from DCF confirming that DCF owed Houbigant $1,139,736.00 under the CPDA. (Id. ¶ 195.) DCF’s argument that “Houbigant had failed to plead that than [sic] the deferral agreements were authorized by the lenders, and thus, those agreements are also void,” are factual arguments that this Court cannot consider on a motion to dismiss. Accordingly, Defendant DCF’s motion to dismiss Count VIII is denied.
G. Count IX — Permanent Injunction
Finally, Houbigant’s ninth cause of action for a permanent injunction must be dismissed because Houbigant has not alleged that it has no adequate remedy at law. Houbigant requests that Defendant IMG Holdings be permanently enjoined both from destroying various records and from making payments to its shareholders. (Countercl. ¶ 256.) Generally, to obtain a permanent injunction “a party must show the absence of an adequate remedy at law and irreparable harm if the relief is not granted.”
New York State Nat’l Org. for Women v. Terry,
CONCLUSION
For the foregoing reasons, Counter-Defendants’ motion to dismiss Counts II through IX of Counter-Plaintiffs Counterclaims [dkt. no. 12] is GRANTED in part and DENIED in part as follows: Counts III, V, VII, and IX are dismissed in their entirety. Count II is dismissed as to Defendants Zohar II and Patriarch but not as to Defendants IMG Brands and DCF. Count VI is dismissed, but Houbigant is granted leave to replead its claim of fraudulent misrepresentation as against IMG Brands in accordance with Fed.R.Civ.P. 9(b). Counts IV and VIII remain in their entirety.
The parties shall confer and inform the Court by letter no later than January 8, 2010 how they propose to proceed.
SO ORDERED:
Notes
. In their Counterclaims, Counter-Plaintiffs detail many of the provisions of the various agreements at issue here. This Background section will outline the parties, the relationship among the parties, and the main contractual provisions. The allegations concerning each specific count of the Counterclaims will be set forth in greater detail in Section II infra.
. The License Agreement is governed by New York Law. (Countercl., Ex. A § 23.)
. Houbigant also alleges, in the alternative, that if Patriarch and Zohar II are not liable for breach of the License Agreement, that they be held, along with Tilton, liable for tortious interference.
. The parties have assumed that New York State law governs Plaintiffs asserted claims, and the Court concludes that New York choice of law rules would point to the application of New York State law.
.
See Staehr v. Hartford Financial Services Group, Inc.,
. For a more thorough discussion of this provision, the Court refers the parties to the Memorandum and Order [dkt. no. 54] in
Houbigant, Inc. et al. v. IMG Fragrance Brands, LLC et al.,
No. 09 Civ. 839(LAP),
